Navigation Links
AVP is Now Avascend
Date:12/5/2007

With an expanded healthcare hospitality service portfolio

SHAWNEE, Kan., Dec. 5 /PRNewswire/ -- AVP Inc., a leader in hospitality services for the healthcare industry, will change its name to Avascend effective December 1, 2007. An integral part of the new brand is the expanded service portfolio and the same unfaltering commitment to patient, guest and employee satisfaction.

Avascend currently provides the following core healthcare hospitality services: Valet Parking, Patient Bellstaff, Wheelchair Escort, Concierge, Room Service, Internal Patient Transportation, Parking Management and Shuttle Transportation. New services include Retail Development, Environmental Services (EVS) and expanded Parking Management and Development.

For more than 20 years, AVP/Avascend has been a leader in logistical solutions and superior guest services. Our passion for serving others, our hospitality experience, and our strong operational infrastructure provide the foundation for serving over 120 hospitals from Alaska to Florida through our more than 1,100 employees.

"Avascend is the first and best Healthcare Hospitality company in the country. Unlike others who specialize in the back-of-house functions like food service or environmental services and unlike other companies who started in the parking business, Avascend has always believed that parking and logistics are ultimately about people. Avascend is a front-of-house company -- focused on not just patient flow and logistics, but the total patient, guest, employee, and physician experience," says Dave Geenens, President/CEO of Avascend.

Avascend's healthcare hospitality services are designed to support patients and visitors during a time when assistance is most valuable, allowing them to focus on their health and the health and experience of their loved ones. Avascend specializes in creating a lasting, positive impression for the customers and employees of healthcare facilities. The result
'/>"/>

SOURCE Avascend
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...reholders to be held on January 8, 2009 , , ...rg International Inc. ("MedEmerg") (OTCBB: MDER), ...es, announced today that it has obtained an interi... concerning its previously announced plan of arran...ealth Group Inc. ("AIM") will acquire all of MedEm...
(Date:11/21/2008)...21 Heska Corporation,(N... the New York Society of,Security Analysts, 12th ...,December 2, 2008 at 1177 Avenue of the Americas, ...heduled to begin at 9:35 a.m. Eastern Time (7:35 a... webcast and for two weeks,following the presenta...
(Date:11/21/2008)...roved effective against Lennox-Gastaut syndrome ,...new drug called Banzel (rufinamide) has been appro... of epilepsy called Lennox-Gastaut syndrome, the U... , The approval was based on results of a four-... to 30. Compared to patients who took a placebo, t...
(Date:11/21/2008)... NursingCenter.com, the premier sit...r reviewed content, has been,updated to improve t...ed,users. Powered by Lippincott Williams & Wi...900 peer-reviewed continuing education activities ... 50 leading nursing journals.,Lippincott Williams...
Breaking Medicine News(10 mins):Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3
...soy protein rich diet may help with fatty liver ac... may often accompanies diabetes.// Dr.Nimbe Torres... de Ciencias Medicas y Nutricion in Mexico, worked...in diabetics and studied its effects on fatty live...
...an and his colleagues from the Stanford University...heir study in the journal Cancer Research. The res...tamin D with pain killers were found to reduce the...r. The study result say that the combination of th...
...05): In an alarming announcement the Health Minist... declared that West Bengal was facing a Dengue epi...easing in comparison to last year.// Mishra also ...typhoid, viral fever and encephalitis were also af...
...Johns Hopkins Department of had discovered a new w...er a heart attack. // The researchers had used a ...o successfully trace stem cells’ destinations afte... body to treat animal hearts damaged by myocardial...
Other Medicine News:Health News:Soy Protein Rich Diet May Help Fatty Liver Of Diabetics 2
(Date:11/19/2008)...re-FirstCall/ -- Amgen,(Nasdaq: AMGN ) and Mill...of,Takeda Pharmaceutical Company Limited (TSE: 40... 3 MONET1 trial evaluating motesanib (AMG 706) in,...he first-line treatment of,advanced non-small cel...ed,following a planned safety data review of 600 ...
(Date:11/19/2008)... , , MONTVALE, N.J., Nov. 19 /PRNewswire-Fi... MEMY ) today announced that it has achieved the ... 3454, its lead alpha-7 nicotinic receptor agonist...renia (CIAS). The Company has randomized 212 pati...on payment from its partner Roche. Memory Pharmac...
(Date:11/18/2008)...f Influenza survey underscores that mothers need t... and Gold Medalist Kristi Yamaguchi joins initiati... While 78 percent of mothers in the United States ...hreatening disease that can strike anyone, only ha...ated this season, according to a new survey from t...
(Date:11/12/2008)...wire/ -- A new study being,published in this Frida...estion, what causes Parkinson,s disease?, One of ...h into,Parkinson,s disease is what causes the sens.... Answering this question has been especially diff... of brain cells that produce,dopamine and they are...
Breaking Medicine Technology:Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 4Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 5Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 6A Window Into Parkinson's Disease 2Booze Taxes Lower Alcohol Linked Deaths 29841 1Booze Taxes Lower Alcohol Linked Deaths 29841 2Booze Taxes Lower Alcohol Linked Deaths 29841 3Best Practice Database Provides Key Findings for Biopharma Product Launch Evaluation 29838 1Best Practice Database Provides Key Findings for Biopharma Product Launch Evaluation 29838 2Caring com and Alzheimer 26apos 3Bs Association Use Social Media to Help Spread Awareness for the Nation 26apos 3Bs Sixth Leading Cause of Death 29835 1Caring com and Alzheimer 26apos 3Bs Association Use Social Media to Help Spread Awareness for the Nation 26apos 3Bs Sixth Leading Cause of Death 29835 2Caring com and Alzheimer 26apos 3Bs Association Use Social Media to Help Spread Awareness for the Nation 26apos 3Bs Sixth Leading Cause of Death 29835 3Best Practice Database Shares Best Practices in Biopharma Public Relations 9196 1Best Practice Database Shares Best Practices in Biopharma Public Relations 9196 2
...Antigen (HLA) region, located on the short arm of ...ion containing about 200 genes. The HLA region is...ity Complex (MHC), and as such contains a set of g...ation. The Class I proteins, classically involved..., are expressed by genes located in the HLA-A, -B ...
...ntributing Editor The first human case of West Nil...ed in Kansas in late June. The CDC has released f...eing 2005,s first documented incidence of the mosq...ve single-stranded RNA flavivirus of about 11 kb. ...umans, horses, and other vertebrates serving as in...
Other Medicine Technology:The Past, Present and Future of HLA Typing 2The Past, Present and Future of HLA Typing 3West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak 2West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak 3West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak 4
...a non-absorbable, lightweight, pre-formed, three-d...ofilament polypropylene with multiple protruding m...nforms to the defect, stays in place, sutures easi...procedure. The soft, flexible mesh minimizes irria...
...aroscopic inguinal hernia repair and urethral susp... biomaterial that enables rapid fixation by tissue...es the answer to the most demanding hernia and sof...inert and conformable ePTFE, GORE MYCROMESH Biomat...
...omaterial is the first hernia repair material with...l operative contamination of the material. This ad...l preservative agents, silver carbonate and chlorh...colonization on the patch for up to 10 days post-i...
...ided ePTFE mesh designed for ventral hernia repair... to minimize visceral attachment to the prosthesis...signed to promote tissue growth. This ingrowth sid...ich is nearly equivalent to polypropylene mesh. Ba...
Medicine Products: